GLUE
Price
$4.87
Change
+$0.14 (+2.96%)
Updated
Jul 3 closing price
Capitalization
299.55M
32 days until earnings call
NWBO
Price
$0.25
Change
-$0.00 (-0.00%)
Updated
Jul 3 closing price
Capitalization
357.27M
Interact to see
Advertisement

GLUE vs NWBO

Header iconGLUE vs NWBO Comparison
Open Charts GLUE vs NWBOBanner chart's image
Monte Rosa Therapeutics
Price$4.87
Change+$0.14 (+2.96%)
Volume$198.93K
Capitalization299.55M
Northwest Biotherapeutics
Price$0.25
Change-$0.00 (-0.00%)
Volume$1.33M
Capitalization357.27M
GLUE vs NWBO Comparison Chart in %
Loading...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NWBO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLUE vs. NWBO commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLUE is a Hold and NWBO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (GLUE: $4.87 vs. NWBO: $0.25)
Brand notoriety: GLUE and NWBO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLUE: 46% vs. NWBO: 56%
Market capitalization -- GLUE: $299.55M vs. NWBO: $357.27M
GLUE [@Biotechnology] is valued at $299.55M. NWBO’s [@Biotechnology] market capitalization is $357.27M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLUE’s FA Score shows that 0 FA rating(s) are green whileNWBO’s FA Score has 0 green FA rating(s).

  • GLUE’s FA Score: 0 green, 5 red.
  • NWBO’s FA Score: 0 green, 5 red.
According to our system of comparison, both GLUE and NWBO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLUE’s TA Score shows that 5 TA indicator(s) are bullish while NWBO’s TA Score has 5 bullish TA indicator(s).

  • GLUE’s TA Score: 5 bullish, 5 bearish.
  • NWBO’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, GLUE is a better buy in the short-term than NWBO.

Price Growth

GLUE (@Biotechnology) experienced а +4.51% price change this week, while NWBO (@Biotechnology) price change was -0.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

GLUE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NWBO($357M) has a higher market cap than GLUE($300M). NWBO YTD gains are higher at: -9.554 vs. GLUE (-29.827). GLUE has higher annual earnings (EBITDA): 6.14M vs. NWBO (-74.92M). GLUE has more cash in the bank: 326M vs. NWBO (2.78M). GLUE has less debt than NWBO: GLUE (41.9M) vs NWBO (69M). GLUE has higher revenues than NWBO: GLUE (159M) vs NWBO (1.47M).
GLUENWBOGLUE / NWBO
Capitalization300M357M84%
EBITDA6.14M-74.92M-8%
Gain YTD-29.827-9.554312%
P/E Ratio40.58N/A-
Revenue159M1.47M10,794%
Total Cash326M2.78M11,731%
Total Debt41.9M69M61%
FUNDAMENTALS RATINGS
NWBO: Fundamental Ratings
NWBO
OUTLOOK RATING
1..100
57
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
62
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GLUENWBO
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
80%
Momentum
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
87%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
86%
Bearish Trend 4 days ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NWBO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ILGJX23.130.28
+1.23%
Columbia Integrated Large Cap Gr Ins 3
WLGRX34.760.35
+1.02%
Macquarie Large Cap Growth Fund R
SAMKX38.460.31
+0.81%
SA US Core Market
RGECX10.620.06
+0.57%
Russell Inv Global Equity C
SHDIX10.080.05
+0.50%
American Beacon Shapiro SMID Cap Eq R5

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with EYPT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
+2.96%
EYPT - GLUE
48%
Loosely correlated
+0.62%
ATXS - GLUE
44%
Loosely correlated
+1.40%
IMNM - GLUE
44%
Loosely correlated
+2.43%
CRSP - GLUE
43%
Loosely correlated
+0.97%
NRIX - GLUE
42%
Loosely correlated
+2.33%
More

NWBO and

Correlation & Price change

A.I.dvisor tells us that NWBO and CCCC have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NWBO and CCCC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NWBO
1D Price
Change %
NWBO100%
+0.85%
CCCC - NWBO
24%
Poorly correlated
-2.63%
CBUS - NWBO
23%
Poorly correlated
+2.65%
XERS - NWBO
23%
Poorly correlated
+0.42%
GLUE - NWBO
22%
Poorly correlated
+2.96%
VRTX - NWBO
21%
Poorly correlated
+0.57%
More